Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Other Operating Expenses (2016 - 2025)

Veracyte (VCYT) has disclosed Other Operating Expenses for 14 consecutive years, with $26.6 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 6.39% to $26.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $123.2 million through Dec 2025, up 20.63% year-over-year, with the annual reading at $123.2 million for FY2025, 20.63% up from the prior year.
  • Other Operating Expenses hit $26.6 million in Q4 2025 for Veracyte, up from $25.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $59.8 million in Q3 2023 to a low of -$64.6 million in Q4 2022.
  • Historically, Other Operating Expenses has averaged $34.9 million across 5 years, with a median of $35.7 million in 2021.
  • Biggest five-year swings in Other Operating Expenses: crashed 227.81% in 2022 and later soared 189.47% in 2023.
  • Year by year, Other Operating Expenses stood at $50.6 million in 2021, then plummeted by 227.81% to -$64.6 million in 2022, then skyrocketed by 189.47% to $57.8 million in 2023, then plummeted by 50.93% to $28.4 million in 2024, then dropped by 6.39% to $26.6 million in 2025.
  • Business Quant data shows Other Operating Expenses for VCYT at $26.6 million in Q4 2025, $25.1 million in Q3 2025, and $46.4 million in Q2 2025.